Pure red-cell aplasia due to anti-erythropoietin antibodies

Nephrology Dialysis Transplantation

Volumn 18, Issue 5, 2003, Pages 865-869

  Eckardt, Kai Uwe ^a   Casadevall, Nicole ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HÔTEL DIEU   (France)

Author keywords

Anti erythropoietin antibodies; Epoetin treatment; Loss of efficacy; Pure red cell aplasia

Indexed keywords

AUTOANTIBODY; CHLORAMPHENICOL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ERYTHROPOIETIN; ERYTHROPOIETIN ANTIBODY; IMMUNOGLOBULIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ANEMIA; CLINICAL FEATURE; DIAGNOSTIC TEST; DISEASE SEVERITY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; EDITORIAL; ERYTHROCYTE APLASIA; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; PATIENT MONITORING; PLASMAPHERESIS; PRIORITY JOURNAL; RASH; RETICULOCYTE COUNT; SCREENING TEST; URTICARIA;

ANTIBODY FORMATION; ERYTHROPOIETIN, RECOMBINANT; HUMANS; RED-CELL APLASIA, PURE; TIME FACTORS;

EID: 0038752054     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg182     Document Type: Editorial

References (15)

1. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 2002; 1: 457-462
2. Bergrem H, Danielson BG, Eckardt K-U, Kurtz A, Stridsberg M. A case of antierythropoietin antibodies following recombinant human erythropoietin treatment. In: Erythropoietin: Molecular Physiology and Clinical Application. Marcel Dekker, New York, NY, 1993: 266-275
3. Peces R, de la Torre M, Alcázar R, Urra JM. Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia. N Engl J Med 1996; 335: 523-524
4. Prabhakar SS, Muhlfelder T. Antibodies to recombinant human erythropoietin causing pure red cell aplasia. Clin Nephrol 1997; 47: 331-335
5. Casadevall N, Dupuy E, Molho-Sabatier P, Tobelem G, Varet B, Mayeux P. Autoantibodies against erythropoietin in a case with pure red-cell aplasia. N Engl J Med 1996; 334: 630-663
6. Casadevall N, Nataf J, Viron B et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346: 469-475
7. Krantz SB. Pure red-cell aplasia. N Engl J Med 1974; 291: 345-350
8. Casadevall N. Antibodies against rHuEPO: native and recombinant. Nephrol Dial Transplant 2002; 17 [Suppl 5]: 42-47
9. Weber G, Gross J, Kromminga A, Loew HH, Eckardt K-U. Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins. J Am Soc Nephrol 2002; 13: 2381-2383
10. Gershon SK, Luksenburg H, Cote TR, Braun MM. Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med 2002; 346: 1584-1586
11. Krüger A, Schröer W, Röhrs F, Vescio G. PRCA in a patient treated with epoetin beta. Nephrol Dial Transplant 2003; 18: 1033-1034
12. Storring PL, Tiplady RJ, Gaines Das RE et al. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol 1998; 100: 79-89
13. Skibeli V, Nissen-Lie G, Torjesen P. Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. Blood 2001; 98: 3626-3634
14. Cavill I, Williams JD. Benefits of recombinant human erythropoietin. Lancet 2002; 360: 1606-1607
15. Bunn HF. Drug-induced autoimmune red-cell aplasia. Editorial. N Engl J Med 2002; 346: 522-523